JP2012509258A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012509258A5 JP2012509258A5 JP2011536348A JP2011536348A JP2012509258A5 JP 2012509258 A5 JP2012509258 A5 JP 2012509258A5 JP 2011536348 A JP2011536348 A JP 2011536348A JP 2011536348 A JP2011536348 A JP 2011536348A JP 2012509258 A5 JP2012509258 A5 JP 2012509258A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- substituted
- alkyl
- peg
- cationic lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002105 nanoparticle Substances 0.000 claims 24
- -1 amino, substituted amino Chemical group 0.000 claims 21
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 20
- 239000000203 mixture Substances 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 235000012000 cholesterol Nutrition 0.000 claims 10
- 108091034117 Oligonucleotide Proteins 0.000 claims 9
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 150000002632 lipids Chemical class 0.000 claims 9
- 229920001223 polyethylene glycol Polymers 0.000 claims 9
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 6
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 6
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 229920000362 Polyethylene-block-poly(ethylene glycol) Polymers 0.000 claims 4
- 230000000692 anti-sense effect Effects 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000002091 cationic group Chemical group 0.000 claims 4
- 229940106189 ceramide Drugs 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 230000000799 fusogenic effect Effects 0.000 claims 3
- 125000004405 heteroalkoxy group Chemical group 0.000 claims 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 3
- 125000006850 spacer group Chemical group 0.000 claims 3
- 108091023037 Aptamer Proteins 0.000 claims 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims 2
- 108700011259 MicroRNAs Proteins 0.000 claims 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108091093037 Peptide nucleic acid Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 230000001588 bifunctional effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims 1
- 108060000903 Beta-catenin Proteins 0.000 claims 1
- 102000015735 Beta-catenin Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 claims 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108091030071 RNAI Proteins 0.000 claims 1
- 108091028664 Ribonucleotide Proteins 0.000 claims 1
- 108091027076 Spiegelmer Proteins 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000002222 downregulating effect Effects 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 239000002336 ribonucleotide Substances 0.000 claims 1
- 125000002652 ribonucleotide group Chemical group 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 1
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 1
- UWYSVYIRGIUDSC-UHFFFAOYSA-N CC(C)CCCC(C)C(CC=C)C(C)(CC1)CC2C1C(C)(CCC(C1)OC(COCCOCCNC(C(CCCCNC3NC3N)NC(N)=N)=O)=O)C1=CC2 Chemical compound CC(C)CCCC(C)C(CC=C)C(C)(CC1)CC2C1C(C)(CCC(C1)OC(COCCOCCNC(C(CCCCNC3NC3N)NC(N)=N)=O)=O)C1=CC2 UWYSVYIRGIUDSC-UHFFFAOYSA-N 0.000 description 1
- IRENVDDCYYVIBT-UHFFFAOYSA-N CC1C(N(C)CCC2)N2CCCC1 Chemical compound CC1C(N(C)CCC2)N2CCCC1 IRENVDDCYYVIBT-UHFFFAOYSA-N 0.000 description 1
- DWXIDAJNMISYJH-UHFFFAOYSA-N CCC(C1OC1N)N=C=N Chemical compound CCC(C1OC1N)N=C=N DWXIDAJNMISYJH-UHFFFAOYSA-N 0.000 description 1
- BWMDMTSNSXYYSP-UHFFFAOYSA-N CCCNC(N)=N Chemical compound CCCNC(N)=N BWMDMTSNSXYYSP-UHFFFAOYSA-N 0.000 description 1
- 0 CC[P@](NCCNC(N)=N)(N=CCC=[O+]CCC(CC(CCC1(C)C2CCC3(C)C(C)C(C)CCCC(C)C)CC1=CCC2C3C=C)=O)=*=CCNC(*)=N Chemical compound CC[P@](NCCNC(N)=N)(N=CCC=[O+]CCC(CC(CCC1(C)C2CCC3(C)C(C)C(C)CCCC(C)C)CC1=CCC2C3C=C)=O)=*=CCNC(*)=N 0.000 description 1
- APKFDBVGPJCXTC-UHFFFAOYSA-N CN1C(CCC2)N2CCC1 Chemical compound CN1C(CCC2)N2CCC1 APKFDBVGPJCXTC-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11530708P | 2008-11-17 | 2008-11-17 | |
| US61/115,307 | 2008-11-17 | ||
| PCT/US2009/052462 WO2010056403A1 (en) | 2008-11-17 | 2009-07-31 | Branched cationic lipids for nucleic acids delivery system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012509258A JP2012509258A (ja) | 2012-04-19 |
| JP2012509258A5 true JP2012509258A5 (enExample) | 2012-07-19 |
Family
ID=42170237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011536348A Withdrawn JP2012509258A (ja) | 2008-11-17 | 2009-07-31 | 核酸送達系のための分岐カチオン性脂質 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110305769A1 (enExample) |
| EP (1) | EP2350296A4 (enExample) |
| JP (1) | JP2012509258A (enExample) |
| CN (1) | CN102216462A (enExample) |
| CA (1) | CA2742689A1 (enExample) |
| TW (1) | TW201019969A (enExample) |
| WO (1) | WO2010056403A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110229581A1 (en) * | 2008-11-17 | 2011-09-22 | Enzon Pharmaceuticals, Inc. | Releasable cationic lipids for nucleic acids delivery systems |
| ME03091B (me) | 2009-12-01 | 2019-01-20 | Translate Bio Inc | Isporuka irnk za povećanje ekspresije proteina i enzima u humanim genetskim oboljenjima |
| EP2527440A1 (en) * | 2011-05-27 | 2012-11-28 | Institut Curie | Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia |
| PT2717893T (pt) | 2011-06-08 | 2019-08-20 | Translate Bio Inc | Composições de nanopartículas lipídicas e métodos para transferência de arnm |
| DK2741765T3 (en) | 2011-08-10 | 2016-06-13 | Adocia | Injectable solution of at least one type of basal insulin |
| US10184151B2 (en) | 2011-10-11 | 2019-01-22 | The Brigham And Women's Hospital, Inc. | Micrornas in neurodegenerative disorders |
| US9579338B2 (en) * | 2011-11-04 | 2017-02-28 | Nitto Denko Corporation | Method of producing lipid nanoparticles for drug delivery |
| CN102516534B (zh) * | 2011-11-14 | 2013-11-20 | 上海交通大学 | 可降解为精胺的聚阳离子及其合成方法、纳米颗粒 |
| CN107583039A (zh) | 2012-01-09 | 2018-01-16 | 阿道恰公司 | Ph为7且至少含pi为5.8至8.5之基础胰岛素和取代共聚(氨基酸)的可注射溶液 |
| US20150267192A1 (en) | 2012-06-08 | 2015-09-24 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
| BR112014030677A2 (pt) | 2012-06-08 | 2022-07-19 | Shire Human Genetic Therapies | distribuição pulmonar de mrna para células-alvo não-pulmonares |
| US20150314003A2 (en) | 2012-08-09 | 2015-11-05 | Adocia | Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer |
| GB201215289D0 (en) * | 2012-08-28 | 2012-10-10 | Medical Res Council | Nanoparticle formulation |
| AU2013355258A1 (en) * | 2012-12-07 | 2015-06-11 | Alnylam Pharmaceuticals, Inc. | Improved nucleic acid lipid particle formulations |
| CA2904151C (en) | 2013-03-14 | 2023-09-12 | Shire Human Genetic Therapies, Inc. | Cftr mrna compositions and related methods and uses |
| KR20150128687A (ko) | 2013-03-14 | 2015-11-18 | 샤이어 휴먼 지네틱 테라피즈 인크. | 메신저 rna의 정제 방법 |
| EA201992208A1 (ru) | 2013-10-22 | 2020-07-31 | Транслейт Био, Инк. | ЛЕЧЕНИЕ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК |
| WO2015061467A1 (en) * | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Lipid formulations for delivery of messenger rna |
| BR112016009014B1 (pt) | 2013-10-22 | 2024-02-06 | Translate Bio, Inc | USO DE COMPOSIÇÃO COMPREENDENDO mRNA PARA DEFICIÊNCIA DE ARGININOSSUCINATO SINTETASE |
| KR102739894B1 (ko) | 2014-04-25 | 2024-12-05 | 샤이어 휴먼 지네틱 테라피즈 인크. | 메신저 rna 의 정제 방법 |
| CN104922068B (zh) * | 2015-05-22 | 2017-10-13 | 江苏凯基生物技术股份有限公司 | 一种Decoy核酸阳离子脂质体载体及其制备方法 |
| ES2879434T3 (es) | 2015-07-23 | 2021-11-22 | Inst Curie | Uso de una combinación de molécula Dbait e inhibidores de PARP para tratamiento del cáncer |
| US11247968B2 (en) | 2015-09-14 | 2022-02-15 | The Board Of Regents Of The University Of Texas System | Lipocationic dendrimers and uses thereof |
| US12318489B2 (en) | 2015-10-26 | 2025-06-03 | Translate Bio Ma, Inc. | Nanoparticle formulations for delivery of nucleic acid complexes |
| WO2017083637A1 (en) | 2015-11-12 | 2017-05-18 | The Board Of Trustees Of The Leland Stanford Junior University | Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery |
| CN112587504B (zh) * | 2016-10-17 | 2022-10-18 | 南京绿叶制药有限公司 | 一种抑制bcl-2的反义寡聚核酸的脂质纳米粒及其制备方法 |
| WO2018081817A2 (en) | 2016-10-31 | 2018-05-03 | University Of Massachusetts | Targeting microrna-101-3p in cancer therapy |
| MX2019010155A (es) | 2017-02-27 | 2020-12-10 | Translate Bio Inc | Arnm de cftr optimizado por codón novedoso. |
| JP7801082B2 (ja) * | 2017-04-20 | 2026-01-16 | シンセナ アーゲー | トリシクロｄｎａヌクレオシドを含む改変オリゴマー化合物およびその使用 |
| WO2018213476A1 (en) | 2017-05-16 | 2018-11-22 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
| CA3071968A1 (en) | 2017-08-04 | 2019-02-07 | Kyowa Kirin Co., Ltd. | Nucleic acid-containing lipid nanoparticle |
| US10435429B2 (en) | 2017-10-03 | 2019-10-08 | Nucorion Pharmaceuticals, Inc. | 5-fluorouridine monophosphate cyclic triester compounds |
| KR102708995B1 (ko) | 2018-01-10 | 2024-09-23 | 누코리온 파마슈티컬스, 인코포레이티드. | 포스포르(포스포론)아미다타세탈 및 포스프(온)아탈세탈 화합물 |
| US11427550B2 (en) | 2018-01-19 | 2022-08-30 | Nucorion Pharmaceuticals, Inc. | 5-fluorouracil compounds |
| CA3092148A1 (en) * | 2018-03-19 | 2019-09-26 | University Of Massachusetts | Modified guide rnas for crispr genome editing |
| WO2020041793A1 (en) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Methods for purification of messenger rna |
| MX2021003421A (es) * | 2018-09-28 | 2021-06-15 | Nutcracker Therapeutics Inc | Formulaciones de nanoparticulas lipidicas que comprenden compuestos peptidicos cationicos lipidados para el suministro de acidos nucleicos. |
| JP7555123B2 (ja) | 2018-10-09 | 2024-09-24 | ザ ユニヴァーシティ オブ ブリティッシュ コロンビア | 有機溶媒不含かつ劣化剤不含のトランスフェクション・コンピテント・ベシクルを含む組成物及びシステム並びにそれらに関連する方法 |
| MX2021005969A (es) | 2018-11-21 | 2021-09-14 | Translate Bio Inc | Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado. |
| AU2020315394A1 (en) | 2019-07-17 | 2022-02-17 | Nucorion Pharmaceuticals, Inc. | Cyclic deoxyribonucleotide compounds |
| WO2021119268A1 (en) * | 2019-12-11 | 2021-06-17 | The General Hospital Corporation | Methods for cell imaging |
| WO2021141944A1 (en) * | 2020-01-07 | 2021-07-15 | Translate Bio Ma, Inc. | Formulations for delivery of oligonucleotides to lung cells |
| US20230041342A1 (en) * | 2020-01-08 | 2023-02-09 | Microvascular Therapeutics, Llc | Alkylated nucleosides, and compositions and methods thereof for nucleic acid delivery |
| EP4093373A1 (en) * | 2020-01-21 | 2022-11-30 | eTheRNA Immunotherapies NV | Lipid nanoparticles |
| EP3865122A1 (en) * | 2020-02-11 | 2021-08-18 | Pantherna Therapeutics GmbH | Lipid composition and use thereof for delivery of a therapeutically active agent to endothelium |
| EP4143199B1 (en) | 2020-04-21 | 2025-11-19 | Ligand Pharmaceuticals, Inc. | Nucleotide prodrug compounds |
| CN115768778A (zh) | 2020-04-21 | 2023-03-07 | 配体药物公司 | 苄氧基磷酸(膦酸)酯化合物 |
| CN114315606B (zh) * | 2020-12-29 | 2023-12-26 | 李斌 | 一种脂样分子及其应用 |
| KR20240008872A (ko) * | 2021-05-06 | 2024-01-19 | 아크투루스 쎄라퓨틱스, 인크. | Rna 전달을 위한 이온화 가능한 양이온성 지질 |
| WO2023107920A1 (en) * | 2021-12-07 | 2023-06-15 | The Trustees Of The University Of Pennsylvania | Anisamide-containing lipids and compositions and methods of use thereof |
| CN114306369B (zh) * | 2021-12-23 | 2023-12-26 | 北京悦康科创医药科技股份有限公司 | 一种硫代寡核苷酸注射液及其制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5972600A (en) * | 1992-04-03 | 1999-10-26 | The Regents Of The University Of California | Separation of active complexes |
| US5777153A (en) * | 1994-07-08 | 1998-07-07 | Gilead Sciences, Inc. | Cationic lipids |
| US5830430A (en) * | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
| DK0888379T3 (da) * | 1996-03-01 | 2001-01-29 | Centre Nat Rech Scient | Forbindelser tilhørende amidinium-familien, farmaceutiske præparater indeholdende disse forbindelser og anvendelsen deraf |
| EP1987845B1 (en) * | 1997-11-20 | 2012-03-21 | Vical Incorporated | Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor. |
| US6320017B1 (en) * | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
| WO2004046327A2 (en) * | 2002-11-14 | 2004-06-03 | Genta Salus Llc | Inhibitory oliogonucleotides targeted to bcl-2 |
| US7713738B2 (en) * | 2003-02-10 | 2010-05-11 | Enzon Pharmaceuticals, Inc. | Oligomeric compounds for the modulation of survivin expression |
| TWI257924B (en) * | 2003-09-22 | 2006-07-11 | Lipotek Inc | Cationic lipid for delivery function, and nanoparticle comprising the same |
| WO2007056861A1 (en) * | 2005-11-18 | 2007-05-24 | Protiva Biotherapeutics, Inc. | Sirna silencing of influenza virus gene expression |
| WO2008043366A2 (en) * | 2006-10-13 | 2008-04-17 | Københavns Universitet | Three-domain compounds for transmembrane delivery |
| CN102231950A (zh) * | 2008-11-17 | 2011-11-02 | 安龙制药公司 | 用于核酸递送系统的可释放聚合脂质 |
| US20110229581A1 (en) * | 2008-11-17 | 2011-09-22 | Enzon Pharmaceuticals, Inc. | Releasable cationic lipids for nucleic acids delivery systems |
-
2009
- 2009-07-31 US US13/129,495 patent/US20110305769A1/en not_active Abandoned
- 2009-07-31 TW TW098125815A patent/TW201019969A/zh unknown
- 2009-07-31 EP EP09826479A patent/EP2350296A4/en not_active Withdrawn
- 2009-07-31 WO PCT/US2009/052462 patent/WO2010056403A1/en not_active Ceased
- 2009-07-31 JP JP2011536348A patent/JP2012509258A/ja not_active Withdrawn
- 2009-07-31 CN CN2009801458870A patent/CN102216462A/zh active Pending
- 2009-07-31 CA CA2742689A patent/CA2742689A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012509258A5 (enExample) | ||
| JP2011529912A5 (enExample) | ||
| JP2011520983A5 (enExample) | ||
| JP2012509366A5 (enExample) | ||
| JP2012509273A5 (enExample) | ||
| DK2431466T3 (en) | Single-stranded nucleic acid molecule for the control of gene expression | |
| US9074208B2 (en) | Modified siRNA molecules and uses thereof | |
| US9006191B2 (en) | Silencing of polo-like kinase expression using interfering RNA | |
| JP2012509272A5 (enExample) | ||
| US20070218122A1 (en) | siRNA silencing of influenza virus gene expression | |
| CA2979998A1 (en) | Compositions and methods for treating hypertriglyceridemia | |
| AU2016201913A1 (en) | Compositions and methods for silencing aldehyde dehydrogenase | |
| US9035039B2 (en) | Compositions and methods for silencing SMAD4 | |
| JP2012532839A5 (enExample) | ||
| RU2010144531A (ru) | Модифицированная липидами двухцепочечная рнк, обладающая мощным эффектом рнк-интерференции | |
| JPWO2020041769A5 (enExample) | ||
| AU2013203219B2 (en) | MODIFIED siRNA MOLECULES AND USES THEREOF | |
| RU2010136047A (ru) | КАТИОННЫЕ siPНК, СИНТЕЗ И ПРИМЕНЕНИЕ В РНК-ИНТЕРФЕРЕНЦИИ | |
| CN120077134A (zh) | 靶向apoc3的多核酸分子及其用途 | |
| Zenkova et al. | Site-specific artificial ribonucleases: conjugates of oligonucleotides with catalytic groups | |
| JPWO2023165595A5 (enExample) | ||
| JPWO2022191567A5 (enExample) | ||
| AU2013202970A1 (en) | Silencing of polo-like kinase expression using interfering RNA | |
| RU2013114396A (ru) | Антисмысловые нуклеиновые кислоты |